Recombinant blood group antigens for serology
The detection of antibodies to blood group antigens is crucial in pre and posttransfusion testing to allow for adequate blood supply of patients requiring blood transfusions. In cases when e.g. antibody mixtures, autoantibodies or alloantibodies to high-prevalence blood group antigens are present, the clear identification could be problematic due to unspecific positive (false positive) or overlapping reactions in antibody screening. Recombinant blood group antigens (rBGA) by imusyn can specifically inhibit antibodies and therefore minimize the risk of incompatible blood transfusions.
Method
- Preincubation of 2 μl rBGA with 25 μl patient serum: neutralization of specific red cell antibodies
- Serum can be used for indirect antiglobulin test with conventional gel card systems (Grifols DG® Gel Coombs, Bio-Rad ID-Card LISS/Coombs)
rBGA Features & Advantages
- Simple test procedure
- Direct antibody identification
- Antibody detection and identification in one step
- Simple and fast detection and identification of alloantibodies to high-prevalence blood group antigens
- Better resolution of antibody mixtures
- Neutralization of clinically insignificant antibodies to high-prevalence antigens in pretransfusion cross-matching
- Faster and safer treatment of immunized patients
- Easy to implement in routine serology
| Art. No. | Name | Description |
|---|---|---|
| 004 010 001 | Chido(a) | vial à 300 µl |
| 004 010 003 | CROM/DAF | vial à 300 µl |
| 004 010 004 | Dombrock(a) | vial à 300 µl |
| 004 010 005 | Dombrock(b) | vial à 300 µl |
| 004 010 006 | Duffy(a) | vial à 300 µl |
| 004 010 007 | Duffy(b) | vial à 300 µl |
| 004 010 008 | Kell-Kp(b)-Js(a) | vial à 300 µl |
| 004 010 009 | Indian(b) | vial à 300 µl |
| 004 010 010 | JMH | vial à 300 µl |
| 004 010 011 | Cellano-Kp(b)-Js(a) | vial à 300 µl |
| 004 010 014 | Landsteiner-Wiener(a) | vial à 300 µl |
| 004 010 015 | Rodgers(a) | vial à 300 µl |
| 004 010 016 | rBGA Scianna1 | vial à 300 µl |
| 004 010 017 | Xg(a) | vial à 300 µl |
| 004 010 018 | Cartwright(a) | vial à 300 µl |
| 004 010 019 | rBGA Kn(a)/DACY | vial à 300 µl |
| 004 010 020 | rBGA YCAD | vial à 300 µl |
| 004 010 021 | rBGA Lutheran(a)/Au(a) | vial à 300 µl |
| 004 010 022 | rBGA Lutheran(b)/Au(b) | vial à 300 µl |
| * | serological tested antigens - all relevant antigens on recombinant proteins are listed in the IFU |
References
Seltsam A, Blasczyk R. Recombinant blood group proteins for use in antibody screening and identification tests. Curr Opin Hematol 2009:16:473-9.
Seltsam A, Wagner F, Lambert M, et al. Recombinant blood group proteins facilitate the detection of alloantibodies to highprevalence antigens and reveal underlying antibodies: results of an international study. Transfusion 2014;54:1823-30.
Seltsam A, Blasczyk R. Recombinant blood group proteins in clinical practice - from puzzling to binary antibody testing. ISBT Science Series 2016; 11:243-249.
Contact Form
Call
+49 (0) 6173 607930
Call from USA/Canada
+1 (888) 352 2196